Archive for October, 2009

BTNX launching promotion campaign for Rapid Response blood glucose meter

BNXXBTNX Inc is launching a promotion campaign, offering its Rapid Response branded blood glucose meters free of charge to those end users who have purchased 100 Rapid Response strips. The Rapid Response blood glucose meter is FDA cleared & CLIA waived. It reads results within 7 seconds, needs only 0.7 microliter blood sample, supports alternate site testing, requires no-cleaning and indicates ketone warning. With the large LCD screen, palm-sized dimensions and one-key operation, the device is the most user-friendly blood glucose meter in the marketplace.

First HIV diagnostic assay approved

OrthoClinicalOrtho Clinical Diagnostics received the FDA approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems. This is the first HIV diagnostic assay approved for an integrated system in the US, allowing laboratories to run HIV and other routine tests on a single testing platform and eliminating the need for expensive batch testing of multiple patient samples.

SpectraScience receives Japanese Patent for its Optical Biopsy Forceps System

SpectraScienceSpectraScience Inc has been awarded Japanese Patent number 4361683 for its Optical Biopsy Forceps System and Method of Sampling Tissue. The invention provides for an optical lumen or lumens that are placed coaxially with the cutting jaws of a biopsy forcep. This allows for an optical reading to be taken from the exact same spot as a physical tissue sample. When used with the WavSTAT Optical Biopsy System, it becomes a diagnostic tool to detect pre-cancer and cancer as well as a therapeutic tool for removal of suspect tissue.  If necessary, the fiber optic can be easily removed so that other tools such as a cytology brush can be inserted coaxially.

FDA okays SpectraScience WavSTAT System

SpectraScienceSpectraScience Inc has received FDA approval for the WavSTAT System. The system is the first commercially available product that incorporates this innovative technology for clinical use. WavSTAT is indicated for use as an adjunct to lower gastrointestinal (GI) endoscopy and is intended for the evaluation of polyps less than one centimeter in diameter, which the physician has not already elected to remove.